Data Trends Report. Encuity. Testosterone Replacement Therapy

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "Data Trends Report. Encuity. Testosterone Replacement Therapy"

Transcription

1 Encuity Data Trends Report Encuity has cost-effective solutions to suit your business needs through our various syndicated services. Encuity Data Trends Report provides insight on how our collective services enhance knowledge of therapeutic markets. Testosterone Replacement Therapy Despite its relatively small market size, testosterone replacement therapy (TRT) has been gaining considerable attention among physicians and consumers due to its core patient base of maturing males and its primary ability to either curb loss of virility or, in some cases, restore virility. TRT, or Low T therapy as it is commonly called, is a hormone therapy for men designed to counteract the effects of diminished activity in the gonads, or hypogonadism. Encuity Research, the industry leader in syndicated market research data, has found that the increase in attention for TRT is likely the result of aggressive direct-to-consumer (DTC) advertising by certain products within the market. Data from Encuity s PromotionalAnswers audit line shows that, in 2009, the top six branded products spent approximately $55 million on promotion, but by 2013 that number had grown five-fold to just over $282 million (Figure 1). The ramp-up of promotional activity is clearly having its desired effect. According to Encuity s TreatmentAnswers audit, over the course of the last five years, the TRT market has seen dramatic growth in patient visits, up 55% from 1.2 million in 2009 to 1.9 million in Physician intent to prescribe has also increased as a result of these visits, up 56% from 1.08 million in 2009 to 1.7 million in 2013 (Figure 2). While data from TreatmentAnwers shows steady growth in the TRT market over the last five years, the recent rise in office visits during the latter part of 2013 and early 2014 might be directly related to negative findings regarding a potential risk of increased cardiovascular events associated with the use of prescription testosterone products. This growth may signal patients visiting their doctors to discuss the potential risks and next steps.

2 Total Promotional Spend for Top TRT Products $300 Figure 1 Total Promotional Spend (Millions) $250 $200 $150 $100 $50 $ Total Market Axiron AndroGel Testim Foretesta Androderm Testopel 2013 Source: Encuity s PromotionalAnswers Visits and Intended Drug Uses for Low T Figure 2 2,000 1,800 Visits/Uses (Thousands) 1,600 1,400 1,200 1, Visits Uses Source: Encuity s TreatmentAnwers 2

3 Links to Cardiovascular Events According to two recent studies, the use of testosterone products may increase the risk of certain cardiovascular events, including heart attack and stroke, sometimes resulting in death. The PLOS ONE study by Finkle et al 1 published in January 2014 and funded by the National Institutes of Health (NIH) reported that within 90 days of taking testosterone treatment, the risk of heart attack can double in men 65 and older, and the risk may triple for men younger than 65. In November 2013, the Vigen et al. study published in JAMA 2 of men in the Veterans Affairs (VA) health system who underwent testosterone therapy showed a 30% higher risk of heart attack, stroke, and death than those who did not use testosterone therapy. As a result of these recent study findings, the US Food and Drug Administration (FDA) announced in late January that it would be investigating the risk of stroke, heart attack, and death in men taking FDA-approved testosterone products. In the announcement, the FDA stated that it had been studying the risk for some time and that the release of the findings in the two above-cited studies suggested that a link may exist between increased cardiovascular events and prescribed testosterone therapy. Critics point to several factors to cast doubt on the results linking testosterone therapy to increased cardiovascular risk: Results in the NIH study were based on prescription claim data of patients who were prescribed testosterone therapy, but it was never verified as to whether or not these patients took the medication. Overall, patients may not have been thoroughly screened via blood testing to see if other factors may have led to increased cardiovascular events. In the Vigen study, prior to study adjustments, a good portion of the men who were identified to have increased risk actually saw their risk of cardiovascular events go down. Regardless of where doctors, researchers, and advocates stand in the debate, the hope is that the FDA-commissioned study will be based on randomized trials to provide evidence-based guidelines for testosterone treatment and move away from the current observational data. 3

4 Visits for TRT Figure 3 250, ,000 NIH Study Released (PLoS One) 150, ,000 Vigen Study Released (JAMA) 50,000 0 Oct-13 Nov-13 Dec-13 Jan-14 Source: Encuity s TreatmentAnswers Observations from Encuity Data Encuity s TreatmentAnswers tracks the interaction between physicians and patients seeking treatment and can shed light on the effects of negative publicity. A key measure within the audit is the ability to track patient visits by therapy area of indication. By looking at the number of patient visits in October 2013, the month prior to the first study, and the following three months ending in January 2014 when the second study was published, we can observe a dramatic increase in patient visits for Low T, which may be a result of patient concerns over the negative study findings. In October 2013, 109,000 office visits for Low T were recorded, but in November, the month of the first study, the number of office visits jumps to 149,000, a 37% increase (Figure 3). In December, the number increases another 3% to 153,000 visits, and in January 2014 the number of visits reaches a high water mark of 232,000, another 51% increase. In total, the number of office visits for Low T increased 113% between October 2013 and January Key Messages In an effort to get ahead of the negative publicity, a few of the key products in the market have targeted physicians with messages specific to cardiovascular risk and the published studies. According to Encuity s DetailAnswers Plus, reps from AbbVie promoting AndroGel and Eli Lilly reps promoting Axiron have woven mentions of cardiovascular risk into their messaging. 4

5 Asked to recall the topics they discussed with reps, physicians surveyed as part of the DetailAnswers Plus audit provided the following example responses: AndroGel (AbbVie): Reviewed formulary coverage, different topics in the medical literature recently, in JAMA article about VA men and Low T and risk for cardiac events or stroke. Discussed overall safety and efficacy. Endocrinologist, Northeast Trying to quell concerns over cardiac risk. Primary Care Physician, Midwest Need to be selective about who you test for low testosterone as it s not appropriate to treat everyone based on blood levels alone; consider age, symptoms, underlying medical illness, increased risks of cardiovascular morbidity and mortality. Primary Care Physician, New England Axiron (Eli Lilly): Need to discuss and decrease talk of cardiovascular risk given recent study findings. Endocrinoogist, West Cardiovascular risk has all of the sudden become a discussion topic. Primary Care Physician, Southwest TRT Market Promotional Spend While the success of any product is firmly dependent on how effective it is in treating the approved indication, there is little doubt that marketing budgets have an effect as well. As we have outlined previously, the marketing spend in the TRT market has exploded over the course of the last five years, growing five-fold from $55 million in 2009 to just under $283 million in Companies in this market including Eli Lilly (Axiron), AbbVie (AndroGel), Auxillium/ GSK (Testim ), and Endo (Fortesta ) have invested heavily in detailing, meetings and events, and DTC to get their messaging out to the key audiences of healthcare practitioners and consumers to promote their products and their key advantages. Many of the key products in the market, such as Testim, Fortesta, and Androderm, have used a more traditional mix of detailing with meetings and events and some epromotion, but spending leaders Axiron and AndroGel have been more aggressive in targeting consumers with DTC advertising (Figure 4). Much of the strategy in utilizing DTC is no doubt tied to the fact the products are produced by large manufacturers with big, existing DTC budgets. However, the DTC strategy may also be due, in part, to the products relatively new entry into the market or the launching of new formulations. 5

6 Promotional Mix for Top TRT Products Figure 4 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% Axiron ($122M) AndroGel ($119M) Testim ($21M) Fortesta ($13M) Androderm ($5M) Testopel ($1M) DTC Physician Detailing NP/PA Detailing Meeting and Events epromo Journal Source: Encuity s PromotionalAnswers Looking at the growth in promotional spend for the TRT market, DTC has been the key driver. In 2013, the TRT market had two of the top 20 products in terms of DTC spend, Axiron (16th) and AndroGel (18th). And in 2013, DTC accounted for 52% of the market s total spend, up from just 9% in 2011 to 38% in Manufacturers have taken note of how successful DTC advertising has been for driving market share in other lifestyle markets, such as erectile dysfunction, dermatology, and eye care. The DTC spend for both Axiron at $84 million and AndroGel at $64 million were higher than the total spends for any other product in the market in Both products utilized television at around the same rate (77% for Axiron and 78% for AndroGel), followed by magazines for the vast majority of their spend allocation (Figure 5). It will be worth observing how the recent publication of potentially negative cardiovascular side effect data will affect spending strategy. Will the marketers of Axiron and AndroGel continue to spend money on DTC advertising despite the negative publicity, or will they go the way of the erectile dysfunction market, in which marketers suspended DTC ads in the face of claims of increased cardiovascular risk? Or will marketers of TRT products redirect DTC money to physician-targeted personal promotion channels in order to ease physician fears? 6

7 Axiron DTC Spend 2013 AndroGel DTC Spend 2013 Figure 5 Newspaper 8% Internet 3% Internet 5% Radio 1% Outdoor 0% Magazine 12% Magazine 16% TV 77% TV 78% Base = $84M Base = $64M Source: Encuity s PromotionalAnswers Conclusion Verbatim comments from Encuity s DetailAnswers Plus show that representatives from some companies in the TRT market are already addressing the increased cardiovascular risk in messaging to their physician targets in recent months. Reps are shown to be both reacting to physician questions and concerns and proactively easing fears of cardiovascular risk. Encuity s PromotionalAnswers shows that companies have increased promotional spend to help foster TRT market growth. Recently, growth in spending has been driven by DTC advertising for market leaders Axiron and AndroGel. However, history has shown that in other markets where safety concerns have arisen, such as erectile dysfunction, promotional efforts may be affected as companies look to switch strategies and engage physicians via personal promotion or move away from promoting their products to patients when a legitimate health risk may be present. 1 Finkle WD et al. Increased Risk of Non-Fatal Myocardial Infarction Following Testosterone Therapy Prescription in Men. PLoS ONE (1). 2 Vigen R et al.association of Testosterone Therapy With Mortality, Myocardial Infarction, and Stroke in Men With Low Testosterone Levels. JAMA (17). For more information about Encuity s services, visit If you have any question about this publication, please contact Jenn Brunner or Gina Barbetta 7

8 The following Encuity services were used for this report: TreatmentAnswers TreatmentAnswers audit is the pharmaceutical and biotech industry s premier drug and diagnosis audit. This audit offers unique insight into physician-intended prescribing habits through quantitative drug and diagnosis analysis. It provides national-level disease state and associated therapy data using a more robust data sample than similar diagnosis audit services. Scan here to download an electronic version of this white paper. PromotionalAnswers Encuity s suite of promotional tracking audits provides insights into the volume of promotional activity and spending in all major channels including detailing, events, epromotion, DTC, professional journals, and sampling. Key reports drawn from the PromotionalAnswers suite include share of voice, marketing mix, and message uptake. DetailAnswers Plus Designed to provide a more granular view of physician detailing, DetailAnswers Plus utilizes company targets, regions, and key prescriber groups to analyze detail/sample volume and share of voice at the region or segment level. DetailAnswers Plus also provides analysis of key quality metrics like detail frequency, reach, rating, formulary, and messaging. Encuity Research is the market research and analytics subsidiary of Campbell Alliance. Encuity s team of skilled market research professionals provides answers that biopharmaceutical leaders need to make critical decisions at enterprise, portfolio, and product levels. Its services span five key areas, including custom qualitative and quantitative market research and analytics, syndicated market research, promotional message tracking, and key opinion leader (KOL) influence mapping. For more information on Encuity and its services, please visit Copyright All Rights Reserved. 8

Acrux (ASX: ACR) 28 April 2014

Acrux (ASX: ACR) 28 April 2014 Acrux (ASX: ACR) 28 April 2014 FORWARD-LOOKING STATEMENTS 2 This presentation includes forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown

More information

For personal use only

For personal use only ACRUX (ACR) - ASX ANNOUNCEMENT 20 FEBRUARY 2014 ACRUX PROVIDES HALF YEAR UPDATE 2013 Highlights: Axiron sales milestone achieved US$25 million receivable early March 2014 Half-year financials: o Revenue

More information

A list of FDA-approved testosterone products can be found by searching for testosterone at http://www.accessdata.fda.gov/scripts/cder/drugsatfda/.

A list of FDA-approved testosterone products can be found by searching for testosterone at http://www.accessdata.fda.gov/scripts/cder/drugsatfda/. FDA Drug Safety Communication: FDA cautions about using testosterone products for low testosterone due to aging; requires labeling change to inform of possible increased risk of heart attack and stroke

More information

Committee Approval Date: October 14, 2014 Next Review Date: March 2015

Committee Approval Date: October 14, 2014 Next Review Date: March 2015 Medication Policy Manual Topic: Testosterone replacement therapy products: - Androderm, - Axiron, - Fortesta, - Striant, - Testim Gel, - Natesto, - Vogelxo Policy No: dru297 Date of Origin: March 15, 2013

More information

February 25, 2014. Dear Dr. Hamburg:

February 25, 2014. Dear Dr. Hamburg: February 25, 2014 Margaret A. Hamburg, M.D. Commissioner Food and Drug Administration Department of Health and Human Services WO 2200 10903 New Hampshire Avenue Silver Spring, MD 20993-0002 Division of

More information

Testosterone; What s all the hype? KRISTEN WYRICK, LTCOL,USAFR, MC USUHS, FAMILY MEDICINE JOINT BASE LANGLEY-EUSTIS

Testosterone; What s all the hype? KRISTEN WYRICK, LTCOL,USAFR, MC USUHS, FAMILY MEDICINE JOINT BASE LANGLEY-EUSTIS Testosterone; What s all the hype? KRISTEN WYRICK, LTCOL,USAFR, MC USUHS, FAMILY MEDICINE JOINT BASE LANGLEY-EUSTIS The faces of Low Testosterone What your patients are seeing Pharmacy Industry Testosterone

More information

TESTOSTERONE REPLACEMENT THERAPY: WHAT YOU NEED TO KNOW ABOUT IT

TESTOSTERONE REPLACEMENT THERAPY: WHAT YOU NEED TO KNOW ABOUT IT TESTOSTERONE REPLACEMENT THERAPY: WHAT YOU NEED TO KNOW ABOUT IT 1 As men get older, their doctors prescribe drugs to replace low testosterone levels in their bodies known as hypogonadism, or more commonly

More information

Medication Policy Manual

Medication Policy Manual Medication Policy Manual Topic: Non-preferred testosterone replacement therapy products (Androderm, Androgel, Aveed, Axiron, Fortesta, Natesto, Striant, Testim Gel, Testopel, Vogelxo, compounded testosterone

More information

NDA 021015 LABELING SUPPLEMENT AND PMR REQUIRED REMS MODIFICATION NOTIFICATION

NDA 021015 LABELING SUPPLEMENT AND PMR REQUIRED REMS MODIFICATION NOTIFICATION DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Silver Spring MD 20993 NDA 021015 LABELING SUPPLEMENT AND PMR REQUIRED REMS MODIFICATION NOTIFICATION AbbVie, Inc. Attention: Gennadiy

More information

Medication Policy Manual. Date of Origin: April 13, 2015. Topic: Testosterone cypionate, testosterone enanthate

Medication Policy Manual. Date of Origin: April 13, 2015. Topic: Testosterone cypionate, testosterone enanthate Medication Policy Manual Topic: Testosterone cypionate, testosterone enanthate Policy No: dru395 Date of Origin: April 13, 2015 Committee Approval Date: December 11, 2015 Next Review Date: April 2016 Effective

More information

PDL Class: Topical Androgens

PDL Class: Topical Androgens Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-945-5220 Fax 503-947-1119 Class Update: Topical Androgens Month/Year of Review:

More information

t!k EUROPEAN MEDICINES AGENCY TESTOSTERONE UPDATE

t!k EUROPEAN MEDICINES AGENCY TESTOSTERONE UPDATE ACRUX (ACR) - ASX ANNOUNCEMENT 24 NOVEMBER 2014 EUROPEAN MEDICINES AGENCY TESTOSTERONE UPDATE The European Medicines Agency (EMA) released a statement regarding the use of Testosterone Replacement Therapy

More information

Neal Rouzier responds to the JAMA article on Men and Testosterone

Neal Rouzier responds to the JAMA article on Men and Testosterone Neal Rouzier responds to the JAMA article on Men and Testosterone On the first day the JAMA article was released I received 500 emails from physicians and patients requesting my opinion of the article

More information

NORTHWEST UROLOGICAL CLINIC, P.C. Physicians and Surgeons N W U C. Testosterone Replacement

NORTHWEST UROLOGICAL CLINIC, P.C. Physicians and Surgeons N W U C. Testosterone Replacement N W U C Testosterone Replacement Low testosterone (low T) is a very common problem in men over 40, and sometimes even in men younger than 40. Men s testosterone levels usually peak in the early 20 s, then

More information

Series 1 PRESCRIPTION DRUG ADVERTISING EXPENSE REPORTING

Series 1 PRESCRIPTION DRUG ADVERTISING EXPENSE REPORTING West Virginia Title 210 LEGISLATIVE RULE GOVERNOR S OFFICE OF HEALTH ENHANCEMENT AND LIFESTYLE PLANNING (GOHELP) Series 1 PRESCRIPTION DRUG ADVERTISING EXPENSE REPORTING 210-1-1. General. 1.1. Scope. --

More information

Scott Byrne & Rachel Weeks G400: Pharma Report 10/22/09 Direct to Consumer Advertising: The Affect on the Pharmaceutical Industry

Scott Byrne & Rachel Weeks G400: Pharma Report 10/22/09 Direct to Consumer Advertising: The Affect on the Pharmaceutical Industry Scott Byrne & Rachel Weeks G400: Pharma Report 10/22/09 Direct to Consumer Advertising: The Affect on the Pharmaceutical Industry A Glance at the Pharmaceutical Industry The pharmaceutical industry is

More information

Prescription drug costs continue to rise at

Prescription drug costs continue to rise at Prescription Drugs Developing an Effective Generic Prescription Drug Program by John D. Jones Pharmacy benefit managers (PBMs) use a variety of pricing strategies. When employers have a thorough knowledge

More information

Great Expectations: Why Pharma Companies Can t Ignore Patient Services

Great Expectations: Why Pharma Companies Can t Ignore Patient Services Accenture Life Sciences Rethink Reshape Restructure... for better patient outcomes Great Expectations: Why Pharma Companies Can t Ignore Patient Services Accenture Research Note: Key findings from a survey

More information

TESTOSTERONE REPLACEMENT THERAPY FOR THE AGING MALE: COUNSELING INSIGHTS FOR THE PHARMACIST TIM DRAKE, PHARM.D.

TESTOSTERONE REPLACEMENT THERAPY FOR THE AGING MALE: COUNSELING INSIGHTS FOR THE PHARMACIST TIM DRAKE, PHARM.D. TESTOSTERONE REPLACEMENT THERAPY FOR THE AGING MALE: COUNSELING INSIGHTS FOR THE PHARMACIST TIM DRAKE, PHARM.D. TESTOSTERONE REPLACEMENT THERAPY FOR THE AGING MALE: COUNSELING INSIGHTS FOR THE PHARMACIST

More information

Anthony Genovese Bayer HealthCare October 9, 2014

Anthony Genovese Bayer HealthCare October 9, 2014 Anthony Genovese Bayer HealthCare October 9, 2014 Disclaimer The view and opinions expressed here today are the views of the author and do not necessarily reflect the official policy or position of Bayer.

More information

Communicating uncertainty about benefits and

Communicating uncertainty about benefits and Communicating uncertainty about benefits and harms of pharmaceutical products Lisa M. Schwartz, MD, MS Steven Woloshin, MD, MS The Dartmouth Institute for Health Policy and Clinical Practice, Dartmouth

More information

Formulary Management

Formulary Management Formulary Management Formulary management is an integrated patient care process which enables physicians, pharmacists and other health care professionals to work together to promote clinically sound, cost-effective

More information

The largest clinical study of Bayer's Xarelto (rivaroxaban) Wednesday, 14 November 2012 07:38

The largest clinical study of Bayer's Xarelto (rivaroxaban) Wednesday, 14 November 2012 07:38 Bayer HealthCare has announced the initiation of the COMPASS study, the largest clinical study of its oral anticoagulant Xarelto (rivaroxaban) to date, investigating the prevention of major adverse cardiac

More information

4. Does your PCT provide structured education programmes for people with type 2 diabetes?

4. Does your PCT provide structured education programmes for people with type 2 diabetes? PCT Prescribing Report Drugs used in Type 2 Diabetes Discussion Points 1. Does your PCT have a strategy for prevention of type 2 diabetes? Does your PCT provide the sort of intensive multifactorial lifestyle

More information

The Cost of Irrational

The Cost of Irrational The Cost of Irrational Medicine Use Margaret Ewen Coordinator, Global Projects (Pricing) Health Action International (HAI) Global Amsterdam PPRI Conference September 2011 Irrational medicine use is widespread

More information

TESTOSTERONE The Future?

TESTOSTERONE The Future? TESTOSTERONE The Future? Martin M. Miner MD Co-Director Men s Health Center The Miriam Hospital Clinical Professor of Family Medicine and Urology Warren Alpert School of Medicine of Brown University Providence,

More information

Pharmaceutical Business Plan Dawn Romvari-Mihalyi Cellular 917-208-7366

Pharmaceutical Business Plan Dawn Romvari-Mihalyi Cellular 917-208-7366 Pharmaceutical Business Plan Dawn Romvari-Mihalyi Cellular 917-208-7366 1.0 Executive Summary 2.0 Situation Analysis 2.1 Market Summary 2.1.1 Market Demographics 2.1.2 Market Needs 2.1.3 Market Trends

More information

Ask your healthcare provider about LONG-ACTING AVEED (testosterone undecanoate) AVEED TESTOSTERONE INJECTION 5 SHOTS A YEAR. Not an actual patient.

Ask your healthcare provider about LONG-ACTING AVEED (testosterone undecanoate) AVEED TESTOSTERONE INJECTION 5 SHOTS A YEAR. Not an actual patient. Ask your healthcare provider about LONG-ACTING AVEED (testosterone undecanoate) AVEED TESTOSTERONE INJECTION 5 SHOTS A YEAR AFTER THE FIRST MONTH OF THERAPY Not an actual patient. CONSUMERS What is the

More information

Talk to your doctor about low testosterone

Talk to your doctor about low testosterone Talk to your doctor about low testosterone Maybe he doesn t find me attractive any more? Maybe he needs to lose some weight? Maybe he s lost his spark? Bayer Pharma AG Müllerstraße 178 13353 Berlin Germany

More information

Type 1 Diabetes ( Juvenile Diabetes)

Type 1 Diabetes ( Juvenile Diabetes) Type 1 Diabetes W ( Juvenile Diabetes) hat is Type 1 Diabetes? Type 1 diabetes, also known as juvenile-onset diabetes, is one of the three main forms of diabetes affecting millions of people worldwide.

More information

Consultation Response Medical profiling and online medicine: the ethics of 'personalised' healthcare in a consumer age Nuffield Council on Bioethics

Consultation Response Medical profiling and online medicine: the ethics of 'personalised' healthcare in a consumer age Nuffield Council on Bioethics Consultation Response Medical profiling and online medicine: the ethics of 'personalised' healthcare in a consumer age Nuffield Council on Bioethics Response by the Genetic Interest Group Question 1: Health

More information

Whitepaper: MSL and Sales Strategies for the US Oncology Market

Whitepaper: MSL and Sales Strategies for the US Oncology Market Whitepaper: MSL and Sales Strategies for the US Oncology Market Oncology: where an expansive market opportunity interests with an extremely high cost of failure. Companies have been built, sold, and failed

More information

Impact of Direct-to-Consumer Advertising on Prescription Drug Spending

Impact of Direct-to-Consumer Advertising on Prescription Drug Spending Impact of Direct-to-Consumer Advertising on Prescription Drug Spending June 2003 The Kaiser Family Foundation is an independent, national health philanthropy dedicated to providing information and analysis

More information

FDA Regulation of Pharmaceutical Marketing. Tom Casola Executive Director Commercial Operations Merck & Co., Inc.

FDA Regulation of Pharmaceutical Marketing. Tom Casola Executive Director Commercial Operations Merck & Co., Inc. FDA Regulation of Pharmaceutical Marketing Tom Casola Executive Director Commercial Operations Merck & Co., Inc. Brief History of Rx Drug Regulation 1931- Food & Drug Administration Established 1938 -

More information

washington national critical critical illness supplemental health insurance Protecting your family, finances and future. CS-PPT

washington national critical critical illness supplemental health insurance Protecting your family, finances and future. CS-PPT washington national critical critical illness supplemental health insurance Protecting your family, finances and future. CS-PPT Simple coverage you can afford Washington National Critical Solutions is

More information

Case Study Analytics as Drivers in Creating a Culture of Wellness

Case Study Analytics as Drivers in Creating a Culture of Wellness Case Study Analytics as Drivers in Creating a Culture of Wellness Launched in 2008 in partnership with Optima Health, Sentara s health insurance division, the wellness program Mission: Health sought to

More information

I am not a prospect I am a partner

I am not a prospect I am a partner IntelliRx, Transforming Prospect to Partner I am not a prospect I am a partner Scalable Systems Life Science & Healthcare Practices Improve Your DNA Data, Numbers & Analytics Intelli Rx Scalable Systems

More information

Testimony of Timothy Coetzee, Ph.D. Representative of a Patient Advocacy Organization President, Fast Forward LLC

Testimony of Timothy Coetzee, Ph.D. Representative of a Patient Advocacy Organization President, Fast Forward LLC Testimony of Timothy Coetzee, Ph.D. Representative of a Patient Advocacy Organization President, Fast Forward LLC Committee on Oversight and Government Reform Domestic Policy Subcommittee U.S. House of

More information

Eighth Annual Online Marketing Effectiveness Benchmarks for the Pharmaceutical Industry

Eighth Annual Online Marketing Effectiveness Benchmarks for the Pharmaceutical Industry Eighth Annual Online Marketing Effectiveness Benchmarks for the Pharmaceutical Industry July 2014 FOR FURTHER INFORMATION, PLEASE CONTACT: John Mangano comscore, Inc. +1 (703) 438-2358 jmangano@comscore.com

More information

PRESCRIPTION MEDICINES: COSTS IN CONTEXT

PRESCRIPTION MEDICINES: COSTS IN CONTEXT PRESCRIPTION MEDICINES: COSTS IN CONTEXT 2015 Since 2000, biopharmaceutical companies have brought MORE THAN 500 NEW TREATMENTS AND CURES to U.S. patients In the last 100 years, medicines have helped raise

More information

Selling Low T Is Big Pharma Taking Big Risks with Patient Safety?

Selling Low T Is Big Pharma Taking Big Risks with Patient Safety? Selling Low T Is Big Pharma Taking Big Risks with Patient Safety? An Overview of the Testosterone Replacement Therapy Marketplace and Potential Risks to Consumers Prepared by the attorneys of the Charles

More information

Predicting Medication Compliance and Persistency

Predicting Medication Compliance and Persistency Predicting Medication Compliance and Persistency By: Jay Bigelow, President Amanda Rhodes, M.P.H., C.H.E.S., Vice President Behavioral Solutions MicroMass Communications, Inc. Introduction A widely recognized

More information

Preparing a New Dermatologic Agent for Market Launch. March, 2011

Preparing a New Dermatologic Agent for Market Launch. March, 2011 Preparing a New Dermatologic Agent for Market Launch March, 2011 The Situation A major pharmaceutical company sought to better understand how physicians treat patients with moderate to severe psoriasis

More information

CARDIAC REHABILITATION Winnipeg Region Annual Report 2013-14

CARDIAC REHABILITATION Winnipeg Region Annual Report 2013-14 CARDIAC REHABILITATION Winnipeg Region Annual Report 2013-14 PROGRAM OVERVIEW The Cardiac Rehabilitation Program (CRP) operates out of two medical fitness facilities in Winnipeg, the Reh- Fit Centre and

More information

Revised 7/05. Copyright 2005 St. Jude Children's Research Hospital www.stjude.org Page 1 of 6

Revised 7/05. Copyright 2005 St. Jude Children's Research Hospital www.stjude.org Page 1 of 6 Antidepressants are drugs used, most often, to treat depression. Depression is a complex illness that involves sad and hopeless feelings that do not go away. Doctors sometimes order these drugs for other

More information

Cloud Marketing: Faces in the Cloud

Cloud Marketing: Faces in the Cloud Robert Groebel September 25, 2015 Features Cloud Marketing: Faces in the Cloud Share this article: facebook twitter linkedin google Comments Email Print As the need for more informed conversations with

More information

COULD IT BE LOW TESTOSTERONE?

COULD IT BE LOW TESTOSTERONE? COULD IT BE LOW TESTOSTERONE? By Dr. Lauren M. Bramley For thousands of years women have been recognized for their sensitivity to hormones. PMS, post partum depression, menopause have long been plights

More information

What is the Cardiovascular Health Awareness Program?

What is the Cardiovascular Health Awareness Program? What is the Cardiovascular Health Awareness Program? 1 What is CHAP? CHAP is a community-based program that brings together local family physicians, pharmacists, volunteers, public health representatives

More information

Call Planning that Delivers on Brand Strategy

Call Planning that Delivers on Brand Strategy SALES FORCE EFFECTIVENESS SUPPLEMENT Call Planning that Delivers on Brand Strategy New Information Sources Determine Prescriber Value BY MATTHEW LINKEWICH AND JAY MARGOLIS, IMS HEALTH The challenge of

More information

Launch Tracking with ZoomRx. A Case Study

Launch Tracking with ZoomRx. A Case Study Launch Tracking with ZoomRx A Case Study CONTENTS Market Situation Unique Challenges Tracking the ZoomRx Way - Process - Key Questions - Unique Insights - ZoomRx Value Learnings & Conclusion cross-functional

More information

Module 11. How to Evaluate Claims of New Heart Failure Treatments and Cures

Module 11. How to Evaluate Claims of New Heart Failure Treatments and Cures Module 11 How to Evaluate Claims of New Heart Failure Treatments and Cures The Heart Failure Society of America (HFSA) is a non-profit organization of health care professionals and researchers who are

More information

Nutrition. Type 2 Diabetes: A Growing Challenge in the Healthcare Setting NAME OF STUDENT

Nutrition. Type 2 Diabetes: A Growing Challenge in the Healthcare Setting NAME OF STUDENT 1 Nutrition Type 2 Diabetes: A Growing Challenge in the Healthcare Setting NAME OF STUDENT 2 Type 2 Diabetes: A Growing Challenge in the Healthcare Setting Introduction and background of type 2 diabetes:

More information

TABLE OF CONTENTS. Source of all statistics:

TABLE OF CONTENTS. Source of all statistics: TABLE OF CONTENTS Executive Summary 2 Internet Usage 3 Mobile Internet 6 Advertising Spend 7 Internet Advertising 8 Display Advertising 9 Online Videos 10 Social Media 12 About WSI 14 Source of all statistics:

More information

An Introduction to PROSTATE CANCER

An Introduction to PROSTATE CANCER An Introduction to PROSTATE CANCER Being diagnosed with prostate cancer can be a life-altering experience. It requires making some very difficult decisions about treatments that can affect not only the

More information

The affordable way to pay for healthcare expenses not covered by your regular health insurance

The affordable way to pay for healthcare expenses not covered by your regular health insurance The affordable way to pay for healthcare expenses not covered by your regular health insurance America s #1 option for individuals and families that have a $2,000 health insurance deductible or more Enroll

More information

Drug Adherence in the Coverage Gap Rebecca DeCastro, RPh., MHCA

Drug Adherence in the Coverage Gap Rebecca DeCastro, RPh., MHCA Drug Adherence in the Coverage Gap Rebecca DeCastro, RPh., MHCA Good morning. The title of my presentation today is Prescription Drug Adherence in the Coverage Gap Discount Program. Okay, to get started,

More information

The Covario SEO Audit Score Industry Rankings. The Pharmaceutical Industry

The Covario SEO Audit Score Industry Rankings. The Pharmaceutical Industry The Covario SEO Audit Score Industry Rankings The Pharmaceutical Industry Direct-to-consumer advertising is the fastest-growing form of marketing in the pharmaceutical industry. Outpacing the growth of

More information

SPECIALTY CASE MANAGEMENT

SPECIALTY CASE MANAGEMENT SPECIALTY CASE MANAGEMENT Our Specialty Case Management programs boost ROI and empower members to make informed decisions and work with their physicians to better manage their health. KEPRO is Effectively

More information

Big Data and Healthcare Information. Ed Reiner Quintiles Transnational

Big Data and Healthcare Information. Ed Reiner Quintiles Transnational Big Data and Healthcare Information Ed Reiner Quintiles Transnational About Me 30 years in the information sector McGraw-Hill Information Division Elsevier Science (Cardiosource, ScienceDirect) Medical

More information

PUBLIC HEALTH OPTOMETRY ECONOMICS. Kevin D. Frick, PhD

PUBLIC HEALTH OPTOMETRY ECONOMICS. Kevin D. Frick, PhD Chapter Overview PUBLIC HEALTH OPTOMETRY ECONOMICS Kevin D. Frick, PhD This chapter on public health optometry economics describes the positive and normative uses of economic science. The terms positive

More information

Understanding the New Digital Healthcare Consumer:

Understanding the New Digital Healthcare Consumer: Understanding the New Digital Healthcare Consumer: Top Trends for DTC Marketers Meredith Ressi President, Manhattan Research mressi@manhattanresearch.com Unauthorized use, redistribution and reproduction

More information

how to choose the health plan that s right for you

how to choose the health plan that s right for you how to choose the health plan that s right for you It s easy to feel a little confused about where to start when choosing a health plan. Some people ask their friends, family, or co-workers for advice.

More information

Media Planning. Marketing Communications 2002

Media Planning. Marketing Communications 2002 Media Planning Marketing Communications 2002 Media Terminology Media Planning - A series of decisions involving the delivery of messages to audiences. Media Objectives - Goals to be attained by the media

More information

White Paper. by Brian Mondry, Vice President, Integrated Strategy & Digital Solutions March 2012

White Paper. by Brian Mondry, Vice President, Integrated Strategy & Digital Solutions March 2012 White Paper Catalysts driving successful decisions in life sciences. Achieving Insights in the US Multiple Sclerosis (MS) Patient Community through a combination of traditional data research and mixed

More information

DCCT and EDIC: The Diabetes Control and Complications Trial and Follow-up Study

DCCT and EDIC: The Diabetes Control and Complications Trial and Follow-up Study DCCT and EDIC: The Diabetes Control and Complications Trial and Follow-up Study National Diabetes Information Clearinghouse U.S. Department of Health and Human Services NATIONAL INSTITUTES OF HEALTH What

More information

Medicare Advantage and Part D Proposed Rule for Contract Year 2015 Prepared for Healthcare Leadership Council. January 2014 Avalere Health LLC 1

Medicare Advantage and Part D Proposed Rule for Contract Year 2015 Prepared for Healthcare Leadership Council. January 2014 Avalere Health LLC 1 Medicare Advantage and Part D Proposed Rule for Contract Year 2015 Prepared for Healthcare Leadership Council January 2014 Avalere Health LLC 1 Overview On January 6, the Centers for Medicare & Medicaid

More information

A Product and Pipeline Analysis of the Multiple Sclerosis Therapeutics Market

A Product and Pipeline Analysis of the Multiple Sclerosis Therapeutics Market A Product and Pipeline Analysis of the Multiple Sclerosis Therapeutics Market Launch of Several Pipeline Oral Products Could Diminish the Market for Injectable Therapies NEC3-52 November 2014 Contents

More information

A Greater Understanding. A Practical Guide to Clinical Trials

A Greater Understanding. A Practical Guide to Clinical Trials A Greater Understanding A Practical Guide to Clinical Trials Solving Insurance and Healthcare AccessProblems I since 1996 A Greater Understanding Patient Advocate Foundation MISSION STATEMENT Patient Advocate

More information

Here is a broad, but certainly not complete list of options for patients to consider when developing a plan to take charge of their IBD treatment:

Here is a broad, but certainly not complete list of options for patients to consider when developing a plan to take charge of their IBD treatment: OLDER ADULTS AND IBD Inflammatory bowel diseases (IBD), such as Crohn s disease and ulcerative colitis, are traditionally diagnosed in younger people. However, the fact that they are life-long diseases

More information

Testosterone Treatment in Older Men

Testosterone Treatment in Older Men Testosterone Treatment in Older Men J. Bruce Redmon, M.D. Professor Division of Endocrinology Departments of Medicine and Urologic Surgery Disclosure Information I have no financial relationships to disclose.

More information

Agenda. I. Current Drivers II. Mandatory Building Blocks III. Quest Diagnostics Approach IV. Early Results and Learning V. Future Drivers VI.

Agenda. I. Current Drivers II. Mandatory Building Blocks III. Quest Diagnostics Approach IV. Early Results and Learning V. Future Drivers VI. Agenda I. Current Drivers II. Mandatory Building Blocks III. Quest Diagnostics Approach IV. Early Results and Learning V. Future Drivers VI. Q&A Consumerism Want control Today s Consumers Are increasingly

More information

Elderly males, especially white males, are the people at highest risk for suicide in America.

Elderly males, especially white males, are the people at highest risk for suicide in America. Statement of Ira R. Katz, MD, PhD Professor of Psychiatry Director, Section of Geriatric Psychiatry University of Pennsylvania Director, Mental Illness Research Education and Clinical Center Philadelphia

More information

Managing Patients with Multiple Chronic Conditions

Managing Patients with Multiple Chronic Conditions Best Practices Managing Patients with Multiple Chronic Conditions Advocate Medical Group Case Study Organization Profile Advocate Medical Group is part of Advocate Health Care, a large, integrated, not-for-profit

More information

A VISION TO TRANSFORM U.S. HEALTH CARE. The programs to make it a reality.

A VISION TO TRANSFORM U.S. HEALTH CARE. The programs to make it a reality. A VISION TO TRANSFORM U.S. HEALTH CARE. The programs to make it a reality. HCI 3 IMPROVING HEALTH CARE QUALITY AND VALUE with evidence-based incentive programs and a fair and powerful model for payment

More information

A CONSUMER'S GUIDE TO CANCER INSURANCE. from YOUR North Carolina Department of Insurance CONSUMER'SGUIDE

A CONSUMER'S GUIDE TO CANCER INSURANCE. from YOUR North Carolina Department of Insurance CONSUMER'SGUIDE A CONSUMER'S GUIDE TO from YOUR North Carolina Department of Insurance CONSUMER'SGUIDE IMPORTANT INFORMATION WHAT IS? Cancer insurance provides benefits only if you are diagnosed with cancer, as defined

More information

Bayer Initiates Rivaroxaban Phase III Study to Support Dose Selection According to Individual Benefit-Risk Profile in Long- Term VTE Prevention

Bayer Initiates Rivaroxaban Phase III Study to Support Dose Selection According to Individual Benefit-Risk Profile in Long- Term VTE Prevention Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Long-term prevention of venous blood clots (VTE): Bayer Initiates Rivaroxaban

More information

News in a Mobile World

News in a Mobile World News in a Mobile World About This Series The business of news continues to change at an astonishingly rapid pace. Like our local news partners, CNN must stay ahead of evolving consumer preferences, new

More information

Cardiovascular Effects of Drugs to Treat Diabetes

Cardiovascular Effects of Drugs to Treat Diabetes Cardiovascular Effects of Drugs to Treat Diabetes Steven E. Nissen MD Chairman, Department of Cardiovascular Medicine Cleveland Clinic Disclosure Consulting: Many pharmaceutical companies Clinical Trials:

More information

Anticipated Date of Discharge Initial Audits

Anticipated Date of Discharge Initial Audits Anticipated Date of Discharge Initial Audits ADOD To follow up on the roll out of the white board documentation of the Anticipated Date of Discharge (ADOD), we have done audits of over 300 white boards

More information

Healthcare as it should be

Healthcare as it should be Healthcare as it should be Affordable, personalized and better consultation with your general practitioner, anytime, anywhere, through a shared services of primary care www.vitalbox.com.br Doctors with

More information

Integrated Approach to Build Patient Adherence: Helping Pharmaceutical Companies to Enhance Growth

Integrated Approach to Build Patient Adherence: Helping Pharmaceutical Companies to Enhance Growth Cognizant White Paper Integrated Approach to Build Patient Adherence: Helping Pharmaceutical Companies to Enhance Growth Executive Summary Pharmaceutical companies have traditionally considered various

More information

Nutraceutical Medical Research, LLC. By: Latesha Richards, Marketing Coordinator

Nutraceutical Medical Research, LLC. By: Latesha Richards, Marketing Coordinator The Value of Conducting Post-Marketing Clinical Research On Marketing Strategy Development Nutraceutical Medical Research, LLC By: Latesha Richards, Marketing Coordinator Those of us who are marketing

More information

In this place, it takes all the running you can do, to stay in the same place. Lewis Carroll Alice Through The Looking Glass

In this place, it takes all the running you can do, to stay in the same place. Lewis Carroll Alice Through The Looking Glass In this place, it takes all the running you can do, to stay in the same place Lewis Carroll Alice Through The Looking Glass By 2010 we are promised (Direct Quotations) Patients will be admitted for treatment

More information

Medicare for Women and Men

Medicare for Women and Men Allsup Medicare Advisor Report Medicare for Women and Men October 2013 Concerns in retirement 2-3 Primary source of income in retirement 4 Financial planner and Medicare discussion 5 Health insurance coverage

More information

http://nurse practitioners and physician assistants.advanceweb.com/features/articles/alcohol Abuse.aspx

http://nurse practitioners and physician assistants.advanceweb.com/features/articles/alcohol Abuse.aspx http://nurse practitioners and physician assistants.advanceweb.com/features/articles/alcohol Abuse.aspx Alcohol Abuse By Neva K.Gulsby, PA-C, and Bonnie A. Dadig, EdD, PA-C Posted on: April 18, 2013 Excessive

More information

Pharmaceutical forecasts address critical business questions for all

Pharmaceutical forecasts address critical business questions for all S A L ES & M A R K E TI NG I N SIGHTS Understanding Your Brand s Performance: Creating Robust Forecasts by Integrating Commercial and Clinical Drivers Art Cook, Nisha Gilra and Eric Persoff Pharmaceutical

More information

Investor News. Not intended for U.S. and UK media

Investor News. Not intended for U.S. and UK media Investor News Not intended for U.S. and UK media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer s Xarelto (Rivaroxaban) Approved for the Treatment of Pulmonary Embolism

More information

For a free consultation about your Testosterone case, please call Davis & Crump at 800-277- 0300.

For a free consultation about your Testosterone case, please call Davis & Crump at 800-277- 0300. Table of Contents Title Page...... 1 Table of Contents.........2 Introduction.....3 Uh Oh. This Wasn't Supposed to Happen. 4 What Did Studies of Testosterone Therapy Really Tell Us?... 6 Andrew Sullivan

More information

Driving Change in U.S. Healthcare Marketing

Driving Change in U.S. Healthcare Marketing Driving Change in U.S. Healthcare Marketing Driving Change in U.S. Healthcare Marketing Page 1 Driving Change in U.S. Healthcare Marketing Aging Public $2.7 Trillion The U.S. healthcare sector is big and

More information

The Patient-Centered Medical Home How Does Managed Care Pharmacy Add Value?

The Patient-Centered Medical Home How Does Managed Care Pharmacy Add Value? The Patient-Centered Medical Home How Does Managed Care Pharmacy Add Value? With heath care reform now being implemented, it is important that managed care pharmacy understand how to provide value for

More information

PHARMACEUTICAL BIGDATA ANALYTICS

PHARMACEUTICAL BIGDATA ANALYTICS PHARMACEUTICAL BIGDATA ANALYTICS ANDINSIGHTS December 2013 Strategic Research Insights, Inc. 2013 Sources of Big Data in rpharmaceutical and Healthcare Industry Challenges with Big Data in Pharma Oncology

More information

XXXXX Petitioner File No. 100383-001 v. Issued and entered this 30 th day of December 2008 by Ken Ross Commissioner ORDER I PROCEDURAL BACKGROUND

XXXXX Petitioner File No. 100383-001 v. Issued and entered this 30 th day of December 2008 by Ken Ross Commissioner ORDER I PROCEDURAL BACKGROUND STATE OF MICHIGAN DEPARTMENT OF LABOR & ECONOMIC GROWTH OFFICE OF FINANCIAL AND INSURANCE REGULATION Before the Commissioner of Financial and Insurance Regulation XXXXX Petitioner File No. 100383-001 v

More information

THE EFFECTIVENESS OF TELEVISION

THE EFFECTIVENESS OF TELEVISION THE EFFECTIVENESS OF TELEVISION Television is changing. TV is no longer just a box in everyone s living rooms, it is now something that can be watched anytime, anywhere, across a range of different screens.

More information

CRITICAL ILLNESS CLAIM FORM

CRITICAL ILLNESS CLAIM FORM CRITICAL ILLNESS CLAIM FORM Critical Illness Claim Form - Instructions Policyholder (employer or plan administrator) Please complete the Policyholder s Statement and ensure that you answer each question

More information

Survey of Physicians About Pharmaceutical and Biotech Research Company Activities and Information

Survey of Physicians About Pharmaceutical and Biotech Research Company Activities and Information Survey of Physicians About Pharmaceutical and Biotech Research Company Activities and Information Nationally representative survey of 508 physicians Survey commissioned by March 2011 www.krcresearch.com

More information

Response to the New Brunswick Government Consultation on a Prescription Drug Plan for Uninsured New Brunswickers

Response to the New Brunswick Government Consultation on a Prescription Drug Plan for Uninsured New Brunswickers Response to the New Brunswick Government Consultation on a Prescription Drug Plan for Uninsured New Brunswickers Brief submitted by The New Brunswick Nurses Union April 2012 Background The New Brunswick

More information

Driving evidence-based decision-making with predictive analytics

Driving evidence-based decision-making with predictive analytics Emma Grundy IBM Predictive Analytics Solution Architect for SPSS Software Driving evidence-based decision-making with predictive analytics Business Analytics software To understand God's thoughts we must

More information

New York City Office of Labor Relations Employee Benefits Program/Municipal Labor Committee

New York City Office of Labor Relations Employee Benefits Program/Municipal Labor Committee New York City Office of Labor Relations Employee Benefits Program/Municipal Labor Committee PICA PRESCRIPTION DRUG PROGRAM Self-Injectable Medications Chemotherapy Medications Questions & Answers Last

More information

What Lies Ahead? Trends to Watch: Health Care Product Development in North America

What Lies Ahead? Trends to Watch: Health Care Product Development in North America What Lies Ahead? Trends to Watch: Health Care Product Development in North America What Lies Ahead? for 2015 DIA has released its third annual What Lies Ahead? report, providing experts insights into the

More information

Saving healthcare costs by implementing new genetic risk tests for early detection of cancer and prevention of cardiovascular diseases

Saving healthcare costs by implementing new genetic risk tests for early detection of cancer and prevention of cardiovascular diseases Saving healthcare costs by implementing new genetic risk tests for early detection of cancer and prevention of cardiovascular diseases Jeff Gulcher, MD PhD Chief Scientific Officer and co-founder decode

More information